Article

LAPR may help reduce reliance on reading glasses

El Paso, TX-Laser presbyopia reversal (LAPR) is showing promise in the treatment of presbyopia in early clinical trials, according to Bobby Maddox, MD.

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Related Content
Multidisciplinary team secures multimillion-dollar award to fund research to achieve a functional human eye transplant
December 3rd 2024

Multidisciplinary team secures multimillion-dollar award to fund research to achieve a functional human eye transplant

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Mazava Project shines light on blindness in Madagascar
November 16th 2024

Mazava Project shines light on blindness in Madagascar

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
November 6th 2024

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007

Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
November 6th 2024

Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery

© 2024 MJH Life Sciences

All rights reserved.